King said in the release that he hopes to conduct a clinical trial using tofacitinib or Jakafi (ruxolitinib, Incyte) for treating vitiligo.
“It’s a first, and it could revolutionize treatment of an awful disease,” King said in the release. “This may be a huge step forward in the treatment of patients with this condition.
The 17-year-old patient suffered from alopecia areata, a disfiguring autoimmune disease that affects tens of millions of people worldwide and has limited treatment options. Alopecia areata may cause spotty hair loss or complete loss of scalp hair, eyebrows, eyelashes and all other body hair. The patient in this study, published Dec. 9 in JAMA Dermatology, had tried multiple treatments with no success.
To treat the condition, Dr. Brett King, assistant professor dermatology, and his co-authors, Dr. Brittany Craiglow and Daniel Tavares, devised a topical formulation of an oral medication used to treat bone marrow diseases.
The drug, ruxolitinib, belongs to a class of medications called JAK inhibitors, which alter the immune system. King had previously used another oral JAK inhibitor, tofacitinib, to restore hair to a male patient with alopecia universalis in 2014, and other researchers have shown that oral ruxolitinib restores hair in this condition, too.
For this study, the patient applied the cream twice a day to the scalp and eyebrows. After 12 weeks, she had complete restoration of eyebrows and partial regrowth of her scalp. After switching from the cream to a pill form to continue her treatment, the patient now has a full head of hair.
The outcome was better than anticipated, said King. “The results with the cream are as good as what is expected with pills over the same amount of time,” he noted. “The results are remarkable.”
A cream is more appropriate for many patients with alopecia areata, including those concerned about possible risks, such as cancer or infections, that have been associated with oral JAK inhibitors, said the researchers. No side effects were observed in the patient using the cream.
“This is a first in the treatment of a devastating and common autoimmune disease and builds on our recent efforts to show that treatment is within reach for millions of people who suffer from alopecia areata and will hopefully continue to build interest in fin
Gilead has publicly declared its interest in a new acquisition, either a company or assets, likely in a mid-range of around $10 billion to $12 billion. In an interview with the Financial Times, Gilead's chief scientist indicated the biotech firm was primarily interested in products which have already passed the proof-of-concept stage........Given the relative dearth of desirable targets for Gilead at this point in the M&A game, analysts see two companies which may make sense for Gilead to acquire—Vertex Pharmaceuticals, maker of Kalydeco and Orkambi, and Incyte, which specializes in cancer and inflammation-related disorders. Wonder which one they will pick?
to you rescue and chime in about impending merger of equals with LLY. At least Jacosa has enough sense to stop these wild predictions
day trading gern as well. got in at $2.02. Missed getting out a couple days ago. U headed back to the sewer pipes in NJ?
Be careful or Boobsie twins will turn you into Yahoo police as threatening or bullying because you don't agree with them. You keep this up I'm gonna flag you as an abuser. wink wink
Pfizer entered into an agreement with BioAtla potentially worth more than $1 billion to develop a new class of antibody therapeutics for the treatment of cancer, BioAtla announced. The companies plan to use BioAtla's Conditionally Active Biologic (CAB) platform in combination with Pfizer's antibody drug conjugate (ADC) payloads. "This agreement...provides an exciting opportunity to further explore innovative and potentially breakthrough technologies in the treatment of human cancers," remarked Bob Abraham, head of Pfizer's Oncology-Rinat R&D group.
Under the agreed terms, Pfizer and BioAtla will each receive a licence to the other's technology to develop and commercialise several CAB-ADC antibodies. Pfizer will additionally receive an exclusive option to develop and commercialise BioAtla's CAB antibodies that target CTLA4.
Meanwhile, both drugmakers are eligible for milestone payments and royalties based on individual CAB-ADC antibody candidates developed and commercialised by the other company. Including the CTLA4 option and licence, BioAtla is eligible to receive more than $1 billion in up-front, regulatory and sales milestone payments, as well as up to double-digit tiered marginal royalties on potential future product sales.
BioAtla noted that CAB-ADC antibodies seek to overcome the inherent limitations of current ADC antibody technology by actively binding to antigens expressed on cancer cells in tumour tissue, but not antigens expressed on normal cells in non-diseased tissues. The drugmaker added that this approach could permit the preferential targeting of tumour tissues by ADCs, thus increasing the efficacy-safety ratios of CAB-ADCs relative to their conventional counterparts.
INCY pumpers are quick on the hairassment and abuse trigger. Must be prejuiced inbreeds from motown. bring it on boobsie twins and sluuzie
BOOOOOOOOBsie twin: Is INCY DRUPing today?
Wrong, he speaks as the market heads into the final hour of trading.....Robert B. Stein, MD, PhD, Chief Scientific Officer and Head of R&D at Agenus will present at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8th at 2:45 p.m. Eastern Time.
Boobsie twins what you say about this?
Move along now folks, nothing to see here on Booobsie twin MrTurd. Yes, on his tombstone it will be written LOOOOOOOOOOSSSSER.
The boobsie twins Made off Maddi & MrTurdinu, won't pick up on this because their to busy in the INCY boiler room bashing honest Joe's like you & me just trying to drink our scotch on the beach enjoying retirement.
Boobsie twin mrturd. glad to see you still have to work. I was able to retire on going both directions on INCY. guess that is why you have to keep working. No move along now folks.
TJ, at least you speak your mind and the truth. Whereas Boobsie twins Jibber & Jabber Madeoff Maddie and MrTurdinu only have dovish fed speak about INCY. Soon JNJ (Jibber & Jabber) will call in reinforcements from Soothing Suzz. Jacosa to the rescue?
Hot stock tips for sale by Maddi
Where's Blue sky Suzz in all this?
DRUP not happening. Where's the mergers? $150 by Friday? Yea right. Loooser boobsie twins: Madeoff Maddie & MrTurdinu